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We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 3 
diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 4 
uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 5 
24,265 individuals of European ancestry from eight European countries. During a mean (SD) 6 
follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. 7 
Higher uric acid associated with higher diabetes risk following adjustment for confounders, 8 
with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic 9 
score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of 10 
uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 11 
59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 12 
1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset 13 
to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06).  In 14 
conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. 15 
Uric acid lowering therapies may therefore not be beneficial in reducing diabetes risk. 16 




Elevated serum uric acid concentrations have been associated with higher diabetes risk in 19 
observational studies(1;2). Meta-analyses reported 6-17%  higher diabetes risk with every 20 
59.48 µmol/L (1 mg/dL) higher uric acid concentration(1;2). If this observed association were 21 
found to be causal, uric acid lowering therapies could be used in diabetes prevention. 22 
However, whether uric acid causes diabetes is still a matter of debate (3;4). Uric acid 23 
concentrations are closely linked to other diabetes risk factors such as obesity, which makes it 24 
difficult to determine the independent effects of uric acid when limited to observational 25 
analysis alone(3;4). Evidence from human intervention studies on the effect of uric acid 26 
lowering therapy on glucose metabolism is very limited and inconsistent(5-7) .  27 
The concept of Mendelian randomization, i.e. using genetic variants as instrumental variable, 28 
can be applied to test and estimate the causal effects of risk factors on disease outcomes(8). 29 
Since alleles are randomly allocated during gamete formation, the association of a genetic 30 
variant with risk of a disease outcome is unlikely to be confounded by other factors. Also, 31 
reverse causality is abrogated. Three meta-analyses together identified 31 loci associated with 32 
uric acid(9-11). Variants at such loci can be used as genetic instruments, to estimate the 33 
unconfounded effect of uric acid on diabetes risk. Only one Mendelian randomization study 34 
on uric acid and diabetes risk has been previously performed(12), and reported no evidence 35 
for a causal effect. That study used a small number of SNPs (8 identified in the first meta-36 
analyses(9)), and used different studies to estimate the association between the genetic sore 37 
and diabetes, the association between the genetic score and uric acid, and the association 38 
between uric acid and diabetes (i.e. the three sides of the Mendelian randomization 39 
triangle(13)).  40 
In the present study, we aimed to estimate the unconfounded effect of uric acid on diabetes 41 
risk, using a multi-locus Mendelian randomization approach. We performed instrumental 42 
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variable estimation within the same study, using data on genetic variants in 24 uric acid 43 
associated loci, and measured uric acid concentrations among 24,265 individuals, including 44 
10,576 incident type 2 diabetes cases.  We then bolstered the sample size by including 45 
summary-level data from the DIAGRAM consortium, bringing our total number of diabetes 46 
cases to 41,508. 47 
 48 
Subjects and methods 49 
 50 
Study population 51 
The EPIC-InterAct study is a large, prospective case-cohort study involving individuals from 52 
eight European countries (Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden, 53 
and the United Kingdom [UK]; 26 study centers), which is nested within the European 54 
Prospective Investigation into Cancer and Nutrition (EPIC)(14). The majority of participants 55 
were aged 35 to 70 years and were recruited between 1991 and 2000, mainly from the general 56 
population. The EPIC-InterAct study, drawn from a total cohort of 340,234 individuals 57 
comprising 3.99 million person–years of follow-up, was designed to investigate the interplay 58 
between genetic and lifestyle factors and type 2 diabetes risk(15). A total of 12,403 verified 59 
incident cases of type 2 diabetes were identified. A center-stratified, random subcohort of 60 
16,154 individuals was selected for analysis. Because of the random selection, this subcohort 61 
also included a random set of 778 individuals who had developed incident type 2 diabetes 62 
during follow-up. All participants gave written informed consent, and the study was approved 63 
by the local ethics committees and the Internal Review Board of the International Agency for 64 
Research on Cancer. 65 
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For the observational part of this analysis, we excluded participants with missing uric acid 66 
(1,873) or co-variable (n=1,641) data, leaving 24,265 (10,576 cases, 14,364 subcohort 67 
participants, including 675 cases in the subcohort) participants for analyses. For the 68 
instrumental variable analysis, we excluded participants with missing uric acid (1,875), 69 
genetic (n= 8,634; including 4,063 from Denmark, since at the time of analysis, genetic data 70 
were not yet available from the Danish cohort), BMI (n=141) or biomarker (n=11) data, 71 
leaving 17,118 (7,319 cases, 10,235 subcohort participants, including 436 cases in the 72 
subcohort) participants for analyses.  73 
 74 
Diabetes 75 
Ascertainment and verification of incident diabetes has been described in detail 76 
elsewhere(15). In short, incident diabetes cases were identified through self-report, linkage to 77 
primary care registers, secondary care registers, medication use and hospital admissions and 78 
mortality data. Information from any follow-up visit or external evidence with a date later 79 
than the baseline visit was used. To increase the specificity of the case definition, we sought 80 
further evidence for all cases with information on incident type 2 diabetes from <2 81 
independent sources at a minimum, including individual review of medical records. 82 
Participants were followed-up for occurrence of diabetes until the 31st of December 2007.  83 
 84 
Uric acid and other biomarkers 85 
Non-fasting blood samples were taken at baseline. Laboratory measures were carried out by 86 
the Stichting Huisartsen Laboratorium Groep (Etten-Leur, the Netherlands) on serum (except 87 
for participants in the Umea center (Sweden), where only plasma samples were available) or 88 
erythrocyte samples that had been previously frozen at either in ultra-low temperature freezers 89 
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at −80°C or in liquid nitrogen. Serum uric acid, triglycerides, glucose and HDL were 90 
measured using a Cobas® enzymatic assay (Roche Diagnostics, Mannheim, Germany) on a 91 
Roche Hitachi Modular P analyser. Erythrocyte HbA1c was measured using Tosoh (HLC-92 
723G8) ion exchange high-performance liquid chromatography on a Tosoh G8. 93 
 94 
Genotyping and construction of the genetic score 95 
DNA was extracted from buffy coat from a citrated blood sample using standard procedures 96 
on an automated Autopure LS DNA extraction system (Qiagen, Hilden, Germany) with 97 
PUREGENE chemistry (Qiagen). In total, 8,536 (3,942 cases, 4,859 subcohort participants, 98 
incluing 265 cases in the subcohort) participants were genotyped with a customised version of 99 
the CardioMetabochip (CardioMetabochip+; Illumina, San Diego, CA, USA), using a 100 
Sequenom iPLEX array (Sequenom, San Diego CA, USA). The remaining participants 101 
(n=8,582; 2,941 cases, 5,812 subcohort participants, including 171 cases in the subcohort) 102 
were genotyped with the Illumina 660W quad chip (Illumina, San Diego, CA, USA), using 103 
TaqMan (Applied Biosystems, Carlsbad, CA, USA). Missing genotypes for participants 104 
genotyped with the Illumina 660W quad chip were imputed by assigning the mean genotype 105 
at each locus for cases and non-cases separately, for individuals successfully genotyped. In 106 
total, genotypes for 15 out of 24 SNPs were imputed. We selected SNPs that passed the 107 
significance threshold of P < 5x 10-8 in three large-scale GWAS meta-analyses of uric acid(9-108 
11) that were identified from searching PubMed with key words ‘GWAS’ and ‘uric acid or 109 
urate’. No SNPs were in linkage disequilibrium with each other. The alleles were coded 0, 1, 110 
2, according to the number of uric acid raising alleles. We then calculated a genetic score by 111 
summing the number of risk alleles. To take into account that effect sizes of individual SNPs 112 
differ, we calculated a weighted genetic score, by weighing the individual SNPs by their 113 
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effect on uric acid, using estimates from the previously published GWAS meta-analyses(9-114 
11).  Online supplementary table 1 provides an overview of the SNPs included in the 115 
genetic score, and weights assigned to each SNP.  116 
  117 
Co-variables 118 
Baseline information on lifestyle, diet and medical history were obtained from self-119 
administered questionnaires. Weight and height were recorded by trained health professionals 120 
during a visit to a study center. Presence of hypertension was defined based on self reported 121 
diagnosis and/or use of medication. Physical activity was assessed by questionnaire and 122 
classified into inactive, moderately inactive, moderately active, and active, according to the 123 
Cambridge Physical Activity Index(16). Glomerular filtration rate (eGFR) was estimated 124 
using the Chronic Kidney Disease Epidemiology Collaboration equation, with creatinine 125 
standardized to the Roche enzymatic method(17). 126 
 127 
Statistical analysis 128 
Associations of individual SNPs with uric acid were assessed with linear regression, among 129 
the participants in the subcohort. Uric acid was modelled per 59.48 µmol/L (1 mg/dL), SNPs 130 
were modelled per uric acid increasing allele (additive model), and associations were adjusted 131 
for study center. Associations of individual SNPs and the uric acid related genetic score (per 132 
SD increase) with incident diabetes were examined with modified Cox regression that 133 
accounted for case-cohort design (Prentice-weighted model(18)), adjusted for study center. 134 
We calculated country specific HRs, and used random-effects meta-analysis to calculate a 135 
pooled HR. We investigated associations of the uric acid related genetic score (per SD 136 
increase) with potential confounders using linear regression for continuous and logistic 137 
regression for dichotomous confounders.  138 
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For the observational association of uric acid and incident diabetes, we estimated country 139 
specific HRs and pooled them through meta-analysis. We used I
2
 to quantify heterogeneity 140 
between countries. Interactions with sex, age and BMI were tested within each country by 141 
including interaction terms in the multivariable models. Country-specific estimates were 142 
pooled as described above. 143 
For the instrumental variable estimate of uric acid on diabetes risk, we used the weighted 144 
genetic score to estimate the unconfounded effect of a 59.48 µmol/L (1 mg/dL) increase in 145 
uric acid on diabetes risk. We applied the two stage control function estimator approach(19) 146 
for this instrumental variable estimate. Instrumental variable estimates were adjusted for study 147 
center, and in a second model sex and BMI were added. Country-specific estimates were 148 
pooled as described above.  The analyses were repeated in strata of sex, age,  BMI, and 149 
duration of follow-up . Furthermore, we generated instrumental variable estimates of uric acid 150 
on glycemic traits (non-fasting glucose and HbA1c) as described above.  151 
Proportional Hazard assumptions were inspected visually using log-minus-log plots, with no 152 
deviations detected. 153 
 154 
Sensitivity analyses 155 
Analyses were repeated after excluding participants with HbA1c >6.5% (N=22,146 for 156 
observational analysis and 15,380 for instrumental variable analysis). Furthermore, the 157 
observational association of uric acid and diabetes was estimated in the population used for 158 
the instrumental variable analysis (N=17,118 instead of 24,265). Moreover, we re-analysed 159 
the instrumental variable estimate of uric acid on diabetes risk using the non-weighted genetic 160 
score, excluding SNPs that were not statistically significantly associated with uric acid in our 161 
study, excluding proxy SNPs with r
2
 < 0.80, and excluding SNPs (rs734553; rs2231142) with 162 




We estimated the power for the Mendelian randomization analysis at a 2-sided alpha of 0.05 165 
based on the sample size and proportion of cases, strength of the genetic instrument, and the 166 
expected causal hazards ratio using the online tool mRnd 167 
(http://glimmer.rstudio.com/kn3in/mRnd/)(20).  168 
 169 
Incorporation of publicly available data from MAGIC and DIAGRAM to bolster power 170 
In order to maximize power, we additionally incorporated data made publicly available by 171 
GWAS consortia. For fasting glucose (n=58,074) and HOMA-IR (n=37,073), we used data 172 
from the MAGIC consortium, which is a collaborative effort that combined data from 173 
multiple GWAS to identify genetic determinants that impact on glycemic and metabolic traits. 174 
Participants were of European ancestry, and genotyped with the Metabochip(21). Data are 175 
publicly available at: http://www.magicinvestigators.org/. For diabetes, we used data from 176 
DIAGRAM consortium, which meta-analysed genetic variants on Metabochip in 34,840 177 
diabetes cases and 114,981 controls from 37 studies (22). All studies participating in 178 
DIAGRAM included both men and women; participants were mainly of European ancestry; 179 
the mean age varied from 43 to 72 years and the mean study-level BMI varied from 25.9 to 180 
33.4 kg/m
2
 among diabetes cases, and from 22.3 to 28.3 kg/m
2
 among controls. Data are 181 
publicly available at http://diagram-consortium.org/downloads.html. 182 
For DIAGRAM, we selected the same 24 SNPs (either directly or in LD>0.85) and extracted 183 
the ORs and accompanying standard errors. Diabetes estimates were meta-analysed with odds 184 
ratios from InterAct (after excluding EPIC-Norfolk, which contributes to DIAGRAM) using 185 
fixed-effects meta-analysis on the log scale, to generate a summary estimate for each SNP and 186 
diabetes risk. We then used pooled SNP-diabetes effect estimates (including up to 41,508 187 
diabetes cases) and external weights from uric acid GWAS (Online supplementary table 1) for 188 
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instrumental variable analysis. In MAGIC, exactly the same process was repeated but without 189 
meta-analysing MAGIC and InterAct (given that fasting glucose and HOMA-IR are not 190 
quantified in InterAct). We generated instrumental variable estimates for each SNP by 191 
dividing each SNP-trait effect estimate by the corresponding SNP-uric acid estimate. The 192 
analysis took into account the uncertainty in both the SNP-trait and SNP-uric acid estimates 193 
by using the delta method to estimate standard errors of instrumental variable ratio 194 
estimates(23). We then pooled instrumental variable estimates across SNPs using fixed-195 
effects meta-analysis to generate the summary causal effects. 196 




The mean (SD) age in the subcohort was 52 (10) years, and 65% was men. The mean (SD) 201 
uric acid concentration was 280 (77) µmol/L among the subcohort and 333 (83) µmol/L 202 
among diabetes cases (Table 1). Mean uric acid ranged from 327 µmol/Lin Italy and Sweden 203 
to 351 µmol/Lin Spain among males, and from 241 µmol/L in Germany to 261 µmol/L in the 204 
Netherlands among women.  205 
 206 
Observational association of uric acid and diabetes 207 
In the observational analysis, uric acid was associated with higher diabetes risk, with a HR of 208 
1.51 (95%CI: 1.42, 1.62) per 59.48 µmol/L (1 mg/dL) uric acid. After adjustment for 209 
confounders, the observed association attenuated but remained present, with a corresponding 210 
HR of 1.20 (95%CI: 1.11, 1.30) in the multivariable model. BMI was the largest contributor 211 
to this attenuation (Table 2). Additional adjustment for red meat and vitamin C did not alter 212 
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the findings (HR 1.22 [95%CI: 1.11, 1.34]). The association remained consistent when we 213 
explored the association using the population selected for the instrumental variable analysis 214 
(HR multivariable model: 1.25 [95%CI: 1.13, 1.38]). Excluding participants with HbA1c 215 
>6.5% yielded a multivariable HR of 1.26 (95%CI: 1.17, 1.36). 216 
Although all country specific HRs directed towards a higher diabetes risk with higher uric 217 
acid concentrations, there was substantial heterogeneity between countries (I
2
 70%, P-value 218 
0.001; Online supplementary figure 1). Heterogeneity remained present when the analyses 219 
were stratified by age, sex, and BMI with no significant interactions for age and sex (P-values 220 
for interaction 0.16 and 0.77, respectively) and borderline significant (P-value 0.06) for BMI 221 
with no substantially different results in BMI strata; data not shown). After excluding Sweden 222 
from the analysis, heterogeneity attenuated substantially, with I
2
 of 48% (P-value 0.07), and 223 
the association remained present (HR 1.17 [95%CI: 1.09, 1.25]). 224 
 225 
Associations of individual SNPs and genetic score with uric acid and diabetes 226 
Individual uric acid associated SNPs were all directly associated with uric acid, with the 227 
strongest association for rs734553 on locus SLC2A9 (Table 3). The individual SNPs were 228 
generally not associated with diabetes risk (Table 3). 229 
The mean (SD) uric acid associated genetic score was 1.55 (0.25) in both the subcohort and 230 
diabetes cases, and normally distributed among the study participants. A one SD higher 231 
genetic score associated with a 17 µmol/L (95%CI: 15, 18) higher uric acid concentration 232 
(Online supplementary table 2). The genetic score explained 4% of the proportion of 233 
variance of uric acid (F-statistic 462). The genetic score did not associate with diabetes risk 234 





Association of genetic score with potential confounders or mediators  238 
The uric acid associated genetic score was associated with higher triglyceride concentrations 239 
(Beta: 0.01 mmol/L [95%CI: 0.001, 0.02] per SD higher genetic score) and a borderline 240 
association was identified with vitamin C intake and physical activity. Remaining potential 241 
confounders or mediators were not associated with the genetic score (Online supplementary 242 
table 3).  243 
 244 
Instrumental variable analysis of uric acid and diabetes 245 
Using the uric acid associated genetic score to estimate the unconfounded effect of uric acid 246 
(per 59.48 µmol/L [1 mg/dL]) on diabetes showed no evidence for an effect (HR 1.01 247 
[95%CI: 0.87, 1.16]). There was no substantial heterogeneity between countries (I
2
 16%, P-248 
value 0.31; Online supplementary figure 3). This did not materially change after further 249 
adjustment for sex and BMI (Table 2). No differential effects were found in subgroups based 250 
on sex, age, BMI and duration of follow-up (Online supplementary table 4). Furthermore, 251 
there was no evidence for an effect of uric acid on glycemic traits (Online supplementary 252 
table 5). 253 
Excluding participants with HbA1c >6.5% yielded a HR of 1.02 (95%CI: 0.89, 1.17). Using 254 
the non-weighted genetic score as the instrumental variable instead of the weighted genetic 255 
score yielded a HR of 0.96 (95%CI: 0.71, 1.30). Excluding SNPs from the weighted genetic 256 
score that were not associated with uric acid in our study did not change our findings (HR 257 
1.02 [95%CI: 0.89, 1.17]), and neither did excluding proxy SNPs with r
2
 < 0.80 (HR 0.99 258 
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(0.85, 1.16). Adjustment for triglycerides, vitamin C and physical activity did not materially 259 
alter the estimate (HR 0.97 [95%CI: 0.82, 1.15]). 260 
Inclusion of DIAGRAM, increasing our dataset to 41,508 diabetes cases yielded a summary 261 
causal estimate of OR 0.99 (95%CI: 0.92, 1.06) (Table 2; Online supplementary figure 4). 262 
Using this combined dataset, exclusion of the two SNPs that most strongly associated with 263 
circulating uric acid (rs734553 in SLC2A9 and/or rs2231142 in ABCG2) did not alter the 264 
summary estimate (Online supplementary table 6).  265 
 266 
Power calculation 267 
Power calculations for our Mendelian randomization analysis are shown in Online 268 
supplementary table 7. In InterAct, we had 100% power to detect a HR of 1.51, 68% power 269 
to detect a HR of 1.20, and 31% power to detect the same effect estimate when we excluded 270 
rs734553. Inclusion of DIAGRAM increased power to detect a HR of 1.2 for all sensitivity 271 
analyses to over 90% (Online supplementary Table 7), meaning that the estimates derived 272 
from the combined analysis (InterAct and DIAGRAM) were well powered for all scenarios. 273 
 274 
Discussion   275 
In this large European case-cohort study, we found a 20% higher diabetes risk per 59.48 276 
µmol/L (1 mg/dL) higher circulating uric acid concentration in multivariable observational 277 
analysis. Instrumental variable analysis did not confirm this association, and suggests no 278 
evidence of a causal effect of circulating uric acid on diabetes risk.  279 
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The results of the observational analysis are in line with previous reports(1;2). Two previous 280 
meta-analyses showed 6-17% higher diabetes risk per 59.48 µmol/L (1 mg/dL) uric acid. We 281 
found a 20% higher risk per 59.48 µmol/L (1 mg/dL) which is comparable to the previous 282 
studies. However, residual confounding and/or reverse causality may explain these 283 
associations, since we did not find evidence for such an association in instrumental variable 284 
analysis. The results of our instrumental variable analysis generally agree with previous 285 
studies. First of all, our findings are in agreement with the previously performed Mendelian 286 
randomization study of uric acid and diabetes, that included fewer uric acid associated loci 287 
and used different studies to estimate the three sides of the Mendelian randomization 288 
triangle(12). Moreover, a study of Yang et al.(11) showed no association of a genetic score 289 
for uric acid with plasma glucose concentrations, in line with our results. Studies that used a 290 
genetic uric acid score or SLC2A9 as instrumental variable also suggested a bystander role for 291 
uric acid in other metabolic and cardiovascular traits, namely metabolic syndrome(24;25), 292 
ischemic heart disease(26), markers of subclinical atherosclerosis(27), markers of 293 
adiposity(28), and triglycerides(29). For blood pressure, the results are mixed, with reports of 294 
no effect(26), reducing effects(30;31), and increasing effects(32) (Online supplementary 295 
Table 8).   296 
There are observations that support a potential causal role of uric acid, whereas others suggest 297 
a bystander role. First of all, hyperinsulinemia decreases renal excretion of uric acid, leading 298 
to increased blood concentrations of uric acid(3), supporting a bystander role. Furthermore, 299 
sub-clinical chronic inflammation may precede the development of diabetes(33), and uric acid 300 
generation may be increased as a result of oxidative stress. Support for a causal role comes 301 
from a recent study showing that intestinal knockdown of uric acid resulted in hyperuricemia 302 
and development of metabolic syndrome in mice(34). Moreover, there are reports that 303 
xanthine oxidase inhibitors (pharmacological agents used to lower uric acid) may improve 304 
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endothelial function, what may reduce insulin resistance(3). However, it has been suggested 305 
that this may represent an additional effect of enzyme inhibition that is unrelated to uric acid, 306 
since therapies other than xanthine oxidase inhibitors that reduce uric acid concentrations did 307 
not show the same benefits to endothelial function(7;35). Inhibition of xanthine oxidase may 308 
improve endothelial function by reduction of oxidative stress instead of lowering of uric acid 309 
(7).   310 
Strengths of our study are its large sample size (especially including data from DIAGRAM, 311 
which provided a cumulative total of over 40,000 diabetes cases and bolstered our power for 312 
sensitivity analyses), heterogeneous European population, and availability of a comprehensive 313 
range of potential confounders. Moreover, uric acid concentrations were available for all 314 
participants, and were measured centrally to optimize comparability of uric acid 315 
concentrations among participants. Furthermore, our findings showed robustness in sensitivity 316 
analysis. A potential limitation of our study includes that the genetic score explained only 4% 317 
of variation in uric acid. The percentage of explained variation is very comparable to previous 318 
Mendelian randomization studies(36), and the corresponding F-statistic was high, indicating 319 
we are unlikely to suffer from weak instrument bias(13). Second, our study investigated the 320 
effect of circulating uric acid in blood, and does not necessarily also reflect effects of 321 
intracellular uric acid. Individual SNPs in the gene score may have differential effects on uric 322 
acid concentration by body compartment(34;37). Despite this, it is not plausible there will be 323 
common pleiotropy among the individual SNPs included in the score, and any pleiotropic 324 
roles of SNPs should be balanced out by use of a polygenic score(38). Third, our study 325 
population was of European ancestry, which limits generalizability to populations of other 326 
ancestries.  327 
Mendelian randomization studies are a valid way to explore evidence for causality, given that 328 
certain assumptions are met. First, there has to be a strong association between the 329 
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instrumental variable and risk factor of interest. All SNPs used in this study have previously 330 
been shown to be strongly associated with uric acid concentrations in large meta-analyses of 331 
genome wide association studies(9-11). Nevertheless, some SNPs did not associate with uric 332 
acid in our study. However, when we excluded those SNPs from the genetic score, the null-333 
association remained present. Moreover, we strengthened our instrumental variable by using a 334 
genetic score of multiple uric acid associated SNPs. No SNPs were in linkage disequilibrium 335 
with each other, which justifies combining those SNPs.  336 
Second, the instrumental variable must be independent of potential confounders (confounders 337 
in the association between uric acid and diabetes).  To test this, we examined the associations 338 
of the genetic score with potential confounders, and found an association with triglycerides. 339 
However, it can be debated whether this is a true confounder, or downstream consequence of 340 
uric acid pathways. Moreover, since we did not find an association of uric acid and diabetes in 341 
instrumental variable analysis, it is not likely that this is explained by the higher risk of 342 
hypertriglyceridemia in individuals with a high genetic score. Indeed, when we additionally 343 
adjusted the instrumental variable estimate of uric acid on diabetes risk for triglycerides, the 344 
null-effect remained. The observed higher triglyceride concentrations suggests that, although 345 
uric acid may not be causally involved in development of diabetes, there may be a separate 346 
causal role for uric acid in this metabolic disorder.  347 
Third, the instrumental variable affects the outcome only through the risk factor of interest. 348 
This assumption is untestable, and should be considered using information on the underlying 349 
biology. None of the SNPs used in this study were in linkage disequilibrium with loci known 350 
to influence diabetes risk(22;39;40), which strengthens this assumption. Moreover, the vast 351 
majority of SNPs identified in the meta-analysis of Kolz et al.(9) were involved in regulating 352 
urate transport across cell membranes, which suggests that these SNPs directly influence uric 353 
acid levels. However, SLC2A9, the strongest uric acid associated locus, does not only 354 
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transport uric acid, but also glucose and fructose(41), and exchanges uric acid for glucose(42), 355 
leaving room for possible pleiotropy. Moreover, SLC2A9 has recently been shown to have 356 
differential effects on urinary and intestinal secretion of uric acid in mouse, suggesting a rise 357 
serum uric acid due to reduced urinary secretion could be counterbalanced by increased 358 
intestinal secretion and decreased portal vein levels(34). Similar contrasting roles have been 359 
reported for ABCG2(37). A sensitivity analysis excluding the SNPs in these loci did not alter 360 
the result (Online supplementary table 6).  361 
In conclusion, our study does not support the hypothesis that circulating uric acid has a causal 362 
effect on diabetes risk. Our findings therefore suggest that increased uric acid concentrations 363 
are a consequence of an adverse metabolic profile, rather than a cause of diabetes, and that 364 
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Table 1. Baseline characteristics of subcohort participants and incident type 
2 diabetes cases of the EPIC-InterAct study* 
 Subcohort Type 2 diabetes 
Age, years  52 (10) 55 (8) 
Male  65 53 
Current smoking 25 25 
Low educational level 40 53 
Physically inactive 59 66 
Alcohol consumption, g/d, median (IQR) 5 (1, 16) 4 (0.4, 17) 
BMI, kg/m
2
 26.0 (4.3) 30.0 (4.8) 
Systolic blood pressure, mmHg 131 (20) 143 (20) 
Diastolic blood pressure, mmHg 81 (11) 87 (11) 
Prevalent hypertension 19 39 
Uric acid, µmol/L 280 (77) 333 (83) 
Triglycerides mmol/L, median (IQR) 1.1 (0.8, 1.6) 1.7 (1.2, 2.5) 
eGFR, mL/min/1.73m
2
 100 (20) 95 (20) 
Non-HDL cholesterol, mmol/L 4.4 (1.2) 5.0 (1.2) 
Non-fasting glucose, mmol/L 5.0 (1.3) 6.4 (2.6) 
HbA1c, % (mmol/mol) 5.5 [0.5] (36 [5]) 6.2 [1.0] (44 [11]) 
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* N = 10,235 subcohort participants and 7,319 incident type 2 diabetes cases; 
values are mean (SD) or %, unless otherwise indicated; BMI: body mass index; 





Table 2. Observational and instrumental variable estimates for the association of circulating uric acid concentrations with 
incident type 2 diabetes* 
Analysis Diabetes cases, N HR (95%CI) per 59.48 µmol/L  
(1 mg/dL) increase in circulating uric acid 
Observational    
Adjusted for center, age and sex 10,576 1.51 (1.42, 1.62) 
Adjusted for center, age, sex, BMI 10,576 1.25 (1.18, 1.33) 
Multivariable model† 10,576 1.20 (1.11, 1.30) 
Instrumental variable using InterAct   
Adjusted for center  7,319  1.01 (0.87, 1.16) 
Adjusted for center, age, sex and BMI 7,319  0.96 (0.76, 1.20) 
Instrumental variable using InterAct and DIAGRAM  OR (95%CI) per 59.48 µmol/L  
(1 mg/dL) increase in circulating uric acid 
Combined analysis 41,508 0.99 (0.92, 1.06) 
* For observational associations, N = 24,265 with 10,576 incident type 2 diabetes cases, estimates were pooled HR (95%CI) 
derived from random effects meta-analysis. For instrumental variable associations in InterAct, N = 17,118 with 7,319 incident type 
2 diabetes cases, estimates were derived from two stage control function estimator approach analysis, and were pooled with 
random effects meta-analysis. For instrumental variable association using InterAct and DIAGRAM, N= 41,508 diabetes cases, and 
123,974 controls. † Adjusted for study center, sex, age (as underlying time scale), BMI, systolic blood pressure, prevalent 
hypertension, nonHDL cholesterol (total – HDL cholesterol), triglycerides, eGFR, alcohol consumption, smoking status, highest 




Table 3. Associations of individual uric acid related SNPs with circulating uric acid and incident type 2 diabetes 
Gene Chr SNP Uric acid 
raising / other 
allele 
Beta (95%CI) for 
uric acid 
concentrations * 
P-value † HR (95%CI) for  
incident diabetes ‡ 
GCKR 2 rs780094 T/C 0.05 (0.02, 0.09) 0.01 0.98 (0.93, 1.03) 
SLC2A9 4 rs734553 T/G 0.36 (0.32, 0.40) < 0.001 1.02 (0.95, 1.09) 
ABCG2 4 rs2231142 T/G 0.19 (0.13, 0.25) < 0.001 0.93 (0.86, 1.01) 
LRRC16A 6 rs742132 A/G 0.04 (0.001, 0.08) 0.04 1.00 (0.95, 1.06) 
RREB1 6 rs675209 T/C 0.08 (0.04, 0.12) < 0.001 1.03 (0.98, 1.08) 
SLC16A9 10 rs12356193 A/G 0.06 (0.01, 0.11) 0.01 1.03 (0.97, 1.09) 
SLC22A11 11 rs17300741 A/G 0.09 (0.05, 0.12) < 0.001 1.00 (0.96, 1.05) 
PDZK1 1 rs12129861 G/A 0.03 (0.004, 0.08) 0.03 1.04 (0.97, 1.12) 
SLC17A1 6 rs1183201 T/A 0.07 (0.04, 0.11) < 0.001 0.97 (0.93, 1.01) 
SLC22A12 11 rs505802 C/T 0.05 (0.01, 0.09) 0.01 1.00 (0.91, 1.09) 
INHBC 12 rs1106766 C/T 0.06 (0.02, 0.11) 0.01 1.07 (1.01, 1.13) 
ORC4L 2 rs2307394 C/T 0.03 (-0.01, 0.06) 0.15 0.99 (0.93, 1.05) 
SFMBT1 3 rs6770152 G/T 0.05 (0.01, 0.09) 0.01 1.06 (1.00, 1.13) 
VEGFA 6 rs729761 G/T 0.07 (0.03, 0.11) < 0.01 0.92 (0.87, 0.97) 
BAZ1B 7 rs1178977 A/G 0.05 (0.01, 0.10) 0.02 1.00 (0.92, 1.09) 
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PRKAG2 7 rs10480300 T/C 0.06 (0.03, 0.10) 0.001 1.00 (0.95, 1.05) 
STC1 8 rs17786744 G/A 0.04 (0.01, 0.08) 0.02 0.97 (0.93, 1.02) 
OVOL1 11 rs642803 C/T 0.03 (-0.01, 0.06) 0.16 1.00 (0.95, 1.06) 
ATXN2 12 rs653178 C/T 0.03 (-0.01, 0.06) 0.16 1.00 (0.95, 1.06) 
UBE2Q2 15 rs1394125 A/G 0.003 (-0.03, 0.04) 0.86 0.99 (0.94, 1.03) 
IGF1R 15 rs6598541 A/G 0.07 (0.03, 0.10) 0.001 1.03 (0.98, 1.08) 
NFAT5 16 rs7193778 C/T 0.06 (0.01, 0.12) 0.02 1.02 (0.95, 1.09) 
MAF 16 rs7188445 G/A 0.03 (-0.01, 0.07) 0.16 0.98 (0.92, 1.04) 
BCAS3 17 rs2079742 T/C 0.02 (-0.02, 0.07) 0.30 1.01 (0.96, 1.08) 
* Beta obtained from linear regression with uric acid modeled per 59.48 µmol/L (1 mg/dL) increase, and SNPs 
modeled per uric acid increasing allele (additive model), adjusted for study center, among 10,235 subcohort 
participants; † P-value for association uric acid related SNPs with uric acid concentrations; ‡ HR and 95%CI 
obtained from random effects meta-analysis using modified Cox regression, adjusted for study center, among 
17,118 participants of which 7,319 were incident diabetes cases. 
 
